Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.


This page shows the publications co-authored by Richard Stone and Maximilian Stahl.
Connection Strength

  1. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol. 2022 Mar 01; 29(2):63-73.
    View in: PubMed
    Score: 0.247
  2. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML? Leuk Lymphoma. 2021 12; 62(14):3318-3319.
    View in: PubMed
    Score: 0.240
  3. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018 11; 59(11):2723-2726.
    View in: PubMed
    Score: 0.189
  4. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug; 7(8):e601-e612.
    View in: PubMed
    Score: 0.055
  5. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leuk Lymphoma. 2020 06; 61(6):1455-1464.
    View in: PubMed
    Score: 0.054
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.